Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment

Giacomo Coltro, Mrinal M. Patnaik

Research output: Contribution to journalReview article

Abstract

Purpose of Review: Chronic myelomonocytic leukemia (CMML) is a clonal hematological malignancy characterized by both dysplastic and proliferative features, with an inherent risk for leukemic transformation. With the help of this review, we aim to summarize key concepts with regards to CMML biology, diagnosis, risk stratification, and therapeutics. Recent Findings: Based on recent studies, CMML is hallmarked by a relatively low genetic complexity, which contrasts with a compelling phenotypical heterogeneity, largely driven by epigenetic mechanisms. Recent advances in the characterization of CMML biology has led to an improvement in risk-stratification, by means of incorporating prognostically relevant gene mutations. This, however, has not significantly impacted available therapies and outcomes continue to remain poor. Summary: Advances in CMML biology have better explained the phenotypic heterogeneity, while continuing to define the genetic and epigenetic landscape. In spite of recent advances, limited effective therapies exist and developing rationally derived therapeutic approaches is much needed.

Original languageEnglish (US)
Article number101
JournalCurrent oncology reports
Volume21
Issue number11
DOIs
StatePublished - Nov 1 2019

Fingerprint

Leukemia, Myelomonocytic, Chronic
Epigenomics
Hematologic Neoplasms
Therapeutics
Mutation
Genes

Keywords

  • Chronic myelomonocytic leukemia
  • Clonal architecture
  • Myelodysplastic syndromes
  • Myeloproliferative neoplasms
  • Prognostication
  • Target therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Chronic Myelomonocytic Leukemia : Insights into Biology, Prognostic Factors, and Treatment. / Coltro, Giacomo; Patnaik, Mrinal M.

In: Current oncology reports, Vol. 21, No. 11, 101, 01.11.2019.

Research output: Contribution to journalReview article

@article{2a31a9dafc704aab93d747b06ead92ea,
title = "Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment",
abstract = "Purpose of Review: Chronic myelomonocytic leukemia (CMML) is a clonal hematological malignancy characterized by both dysplastic and proliferative features, with an inherent risk for leukemic transformation. With the help of this review, we aim to summarize key concepts with regards to CMML biology, diagnosis, risk stratification, and therapeutics. Recent Findings: Based on recent studies, CMML is hallmarked by a relatively low genetic complexity, which contrasts with a compelling phenotypical heterogeneity, largely driven by epigenetic mechanisms. Recent advances in the characterization of CMML biology has led to an improvement in risk-stratification, by means of incorporating prognostically relevant gene mutations. This, however, has not significantly impacted available therapies and outcomes continue to remain poor. Summary: Advances in CMML biology have better explained the phenotypic heterogeneity, while continuing to define the genetic and epigenetic landscape. In spite of recent advances, limited effective therapies exist and developing rationally derived therapeutic approaches is much needed.",
keywords = "Chronic myelomonocytic leukemia, Clonal architecture, Myelodysplastic syndromes, Myeloproliferative neoplasms, Prognostication, Target therapy",
author = "Giacomo Coltro and Patnaik, {Mrinal M.}",
year = "2019",
month = "11",
day = "1",
doi = "10.1007/s11912-019-0855-6",
language = "English (US)",
volume = "21",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "11",

}

TY - JOUR

T1 - Chronic Myelomonocytic Leukemia

T2 - Insights into Biology, Prognostic Factors, and Treatment

AU - Coltro, Giacomo

AU - Patnaik, Mrinal M.

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Purpose of Review: Chronic myelomonocytic leukemia (CMML) is a clonal hematological malignancy characterized by both dysplastic and proliferative features, with an inherent risk for leukemic transformation. With the help of this review, we aim to summarize key concepts with regards to CMML biology, diagnosis, risk stratification, and therapeutics. Recent Findings: Based on recent studies, CMML is hallmarked by a relatively low genetic complexity, which contrasts with a compelling phenotypical heterogeneity, largely driven by epigenetic mechanisms. Recent advances in the characterization of CMML biology has led to an improvement in risk-stratification, by means of incorporating prognostically relevant gene mutations. This, however, has not significantly impacted available therapies and outcomes continue to remain poor. Summary: Advances in CMML biology have better explained the phenotypic heterogeneity, while continuing to define the genetic and epigenetic landscape. In spite of recent advances, limited effective therapies exist and developing rationally derived therapeutic approaches is much needed.

AB - Purpose of Review: Chronic myelomonocytic leukemia (CMML) is a clonal hematological malignancy characterized by both dysplastic and proliferative features, with an inherent risk for leukemic transformation. With the help of this review, we aim to summarize key concepts with regards to CMML biology, diagnosis, risk stratification, and therapeutics. Recent Findings: Based on recent studies, CMML is hallmarked by a relatively low genetic complexity, which contrasts with a compelling phenotypical heterogeneity, largely driven by epigenetic mechanisms. Recent advances in the characterization of CMML biology has led to an improvement in risk-stratification, by means of incorporating prognostically relevant gene mutations. This, however, has not significantly impacted available therapies and outcomes continue to remain poor. Summary: Advances in CMML biology have better explained the phenotypic heterogeneity, while continuing to define the genetic and epigenetic landscape. In spite of recent advances, limited effective therapies exist and developing rationally derived therapeutic approaches is much needed.

KW - Chronic myelomonocytic leukemia

KW - Clonal architecture

KW - Myelodysplastic syndromes

KW - Myeloproliferative neoplasms

KW - Prognostication

KW - Target therapy

UR - http://www.scopus.com/inward/record.url?scp=85075058812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075058812&partnerID=8YFLogxK

U2 - 10.1007/s11912-019-0855-6

DO - 10.1007/s11912-019-0855-6

M3 - Review article

C2 - 31728739

AN - SCOPUS:85075058812

VL - 21

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 11

M1 - 101

ER -